Our research aims to model the process of tumorigenesis by posing questions that could lead to clinically applicable preventive or therapeutic options, or could form the basis for clinical trials. Our projects focus largely on cancer prevention options, using genomic, biochemical and pharmacological approaches.
Through previous high-throughput screening (HTS) studies, we have identified several potential breast cancer prevention drug combinations, the molecular mechanisms of which provide new prevention targets due to their synergy.
Our areas of interest are the mechanisms of action of nuclear receptor ligands, e.g. rexinoids, monoaminergic transmitters, and their modulators in the inhibition of carcinogenesis. We investigate the effects of genomic remodeling, neurotransmitters, and protein serotonylation on cell proliferation, transformation, and genome stability. We also study lipid metabolism processes as potential therapeutic targets in breast cancer.